CORRELATED STUDIES OF A RECOMBINANT INFLUENZA-VIRUS VACCINE .3. PROTECTION AGAINST EXPERIMENTAL INFLUENZA IN MAN
CORRELATED STUDIES OF A RECOMBINANT INFLUENZA-VIRUS VACCINE .3. PROTECTION AGAINST EXPERIMENTAL INFLUENZA IN MAN
复制标题
DOI：
10.1093/infdis/124.5.473
复制
发表时间：
1971-01-01
影响因子：
6.4
通讯作者：
KASEL, JA
中科院分区：
文献类型：
--
作者：
COUCH, RB;DOUGLAS, RG;KASEL, JA
对51名健康成年志愿者分别接种重组（X-31）甲2型流感疫苗（香港变种）和标准甲2型流感疫苗（香港变种）。一个月后，29名接种疫苗的志愿者和14名对照志愿者用香港变异株的感染性毒株进行了攻击。另外22名志愿者接受了第二次疫苗接种。所有接种疫苗的志愿者血清中和抗体均升高，第二次接种后观察到极轻微升高。在接受活病毒攻击的29名志愿者中，有25名志愿者的神经氨酸酶抑制（NI）抗体因接种疫苗而显著升高。在29名受试者中，有14名鼻分泌物中的中和抗体升高，但只有5名受试者出现NI抗体升高。对于每个地点的每种抗体，重组疫苗的抗原性略高，这一发现与其含有略多抗原的建议（556对503鸡细胞凝集单位）相一致。活病毒攻毒后，与对照组相比，两个接种组的感染和疾病频率均降低。鼻洗液标本中病毒的定量分析揭示了病毒脱落量与临床疾病之间的相关性。血清中NI抗体滴度与病毒脱落减少相关性最好，但不能排除中和抗体的作用。从接种疫苗的血清学应答和对活病毒攻击的保护作用，可以得出结论，重组疫苗与标准A2流感疫苗一样有效。
A recombinant (X-31) influenza A2vaccine (Hong Kong variant) and a standard A2vaccine (Hong Kong variant) were given to 51 normal adult volunteers. One month later, 29 vaccinated and 14 control volunteers were challenged with an infectious strain of the Hong Kong variant. The other 22 volunteers were given a second vaccination. All vaccinated volunteers developed a rise in neutralizing antibody in serum, and a minimal increase was noted from the second vaccination. Twenty-five of the 29 volunteers who were challenged with live virus showed a significant rise in neuraminidase-inhibiting (NI) antibody from vaccination. A rise in neutralizing antibody in nasal secretions was seen in 14 of 29, but only five subjects developed a rise in NI antibody. For each type of antibody in each location, the recombinant vaccine was slightly more antigenic, a finding compatible with the suggestion that it contained slightly more antigen (556 versus 503 chick-cell-agglutinating units). After challenge with live virus, a reduction in frequency of infection and illness was noted in both vaccinated groups when compared to controls. Quantification of virus in specimens of nasal wash revealed an association between quantity of virus shed and clinical illness. Titers of NI antibody in serum correlated best with reduced shedding of virus, but an effect of neutralizing antibody could not be excluded. From the serologic responses to vaccination and the protection afforded against live-virus challenge, it was concluded that the recombinant vaccine was as effective as a standard A2influenza vaccine.